Documents
Médias
Keryx Biopharmaceuticals Initiates Phase 2 Study of Zerenex™ (ferric citrate) for the Treatment of Patients with Non-Dialysis Dependent Chronic Kidney Disease
Editeur
KERYX-BIOPHARMACEUTICALS-INC1
Publications
(
1
)